Massmutual Trust Co. FSB ADV Boosts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Massmutual Trust Co. FSB ADV grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 20.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 831 shares of the medical equipment provider’s stock after buying an additional 140 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Hologic were worth $62,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Graypoint LLC grew its holdings in Hologic by 3.9% during the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after buying an additional 147 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Hologic by 0.3% in the fourth quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock valued at $4,810,000 after acquiring an additional 172 shares during the period. Lincoln National Corp grew its stake in Hologic by 4.0% during the fourth quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock valued at $334,000 after acquiring an additional 178 shares in the last quarter. Allworth Financial LP increased its holdings in Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 179 shares during the period. Finally, Parallel Advisors LLC lifted its stake in Hologic by 11.5% in the 4th quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 189 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.1 %

Shares of Hologic stock traded up $0.09 on Tuesday, hitting $82.45. The stock had a trading volume of 1,781,384 shares, compared to its average volume of 1,649,319. The company has a quick ratio of 3.29, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.15. The stock’s 50-day simple moving average is $75.51 and its two-hundred day simple moving average is $75.42. The stock has a market cap of $19.15 billion, a price-to-earnings ratio of 42.64, a PEG ratio of 2.64 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.93 EPS. As a group, sell-side analysts predict that Hologic, Inc. will post 4.08 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on HOLX. Argus raised their price target on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, July 30th. StockNews.com upgraded Hologic from a “buy” rating to a “strong-buy” rating in a research report on Friday. Royal Bank of Canada raised their target price on shares of Hologic from $81.00 to $82.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 30th. Finally, Evercore ISI increased their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.60.

Insider Buying and Selling at Hologic

In other news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Hologic news, insider Stephen P. Macmillan 44,039 shares of the stock in a transaction that occurred on Tuesday, July 30th. The was disclosed in a filing with the SEC, which is available through this link. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The disclosure for this sale can be found here. Insiders sold 17,804 shares of company stock valued at $1,430,413 in the last 90 days. Insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.